

COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: INDUCTION OF MUCOSAL IMMUNITY BY VACCINATION VIA THE SKIN ROUTE the specification of which

\_\_\_\_\_ is attached hereto

X was filed on November 9, 2000, and assigned Serial No. 09/710,104.

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge and understand that I am an individual who has a duty to disclose information which is material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §§ 1.56(a) and (b) which state:

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or

attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a *prima facie* case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

- (i) Opposing an argument of unpatentability relied on by the Office, or
- (ii) Asserting an argument of patentability.

A *prima facie* case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

I do not know and do not believe this invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application. This invention was not in public use or on sale in the United States of America more than one year prior to this application. This invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than six months prior to this application.

I hereby claim priority benefits under Title 35, United States Code §119(E)(1) of any United States provisional application(s) for patent as indicated below and have also identified below any application for patent on this invention having a filing date before that of the application for patent on which priority is claimed:

	Date of Filing (day/month/year)	Priority Claimed Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
<u>Application No.</u> 60/164,529	10 November 1999	

I hereby appoint the following attorneys and agents to prosecute that application and to transact all business in the Patent and Trademark Office connected therewith and to file, to prosecute and to transact all business in connection with all patent applications directed to the invention:

Thomas P. McCracken, Reg. No. 38,548

Address all correspondence to: Thomas P. McCracken at:

POWDERJECT TECHNOLOGIES, INC.  
6511 Dumbarton Circle  
Fremont, CA 94555  
Telephone: (510) 742-9700  
Facsimile: (510) 742-9720

Address all telephone calls to: Thomas P. McCracken at (510) 742-9700, extension 209.

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Dexiang CHEN

Citizenship: China

Residence: Madison, WI

Post Office Address: 585 Science Drive, Madison, Wisconsin 53711

Signature: Dexiang Chen

Date 4-10-01

Full Name of Inventor: Sangeeta BHARGAVA

Citizenship: India

Residence: Madison, WI

Post Office Address: 585 Science Drive, Madison, Wisconsin 53711

Signature: Sangeeta Bhargava

Date 4/16/01

Full Name of Inventor: Deborah FULLER

Citizenship: U.S.A.

Residence: Madison, WI

Post Office Address: 585 Science Drive, Madison, Wisconsin 53711

Signature: Deborah Fuller

Date 10 April 01

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on \_\_\_\_\_.

Date \_\_\_\_\_

Signature \_\_\_\_\_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Serial No.: 09/710,104 Art Unit: 1648

Filing Date: 09 Nov 2000 Examiner: BROWN, STACY S

Title: Induction of Mucosal Immunity by Vaccination via the Skin Route

**ASSOCIATE POWER OF ATTORNEY  
UNDER 37 C.F.R. § 1.34**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, the undersigned attorney of record in the above-referenced patent application, do hereby grant associate power of attorney to prosecute this application and any continuations, divisions, reissues and reexaminations thereof, and transact all business in the United States Patent and Trademark Office connected therewith, to the following registered attorneys and agents:

Alisa A. Harbin, Reg. No. 33,895;  
the registered attorneys and agents of Foley & Lardner at Customer Number 23524;

Richard C. Peet, Reg. No. 35,792;  
Jayme Huleatt, Reg. No. 34,485;  
Frederic Tenney, Reg. No. 47,131;  
Amy Rocklin, Reg. No. 47,033;  
Alison Scheidler, Reg. No. 54,425;

Atty Dkt No.APF 38.20  
USSN: 09/710,104  
PATENT

Eve Frank, Reg. No. 46,785;  
Robert P. Blackburn, Reg. No. 30,447;  
Joseph H. Guth, Reg. No. 31,261;  
Charlene A. Launer, Reg. No. 33,035;  
Rebecca M. Hale, Reg. No. 45,680;  
Steven W. Collier, Reg. No. 42,429;  
Marcella Lillis, Reg. No. 36,583; and  
Gerald Suh, Reg. No. 41,337.

Please address all future correspondence relating to this application to:

Alisa A. Harbin  
Chiron Corporation  
4560 Horton Street, M/S R-338  
Emeryville, California 94608-2916  
United States of America  
Tel: (510) 923-2708  
Fax: (510) 655-3542

Respectfully submitted,

By:   
Thomas P. McCracken  
Registration No. 38,548

POWDERJECT PHARMACEUTICALS PLC.  
Florey House  
The Oxford Science Park  
Oxford OX4 4GA  
United Kingdom  
Telephone: +44 1865 332 600  
Fax: +44 1865 332 601